PD173074 NEW
| Price | $36 | $52 | $91 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: PD173074 | CAS No.: 219580-11-7 |
| Purity: 98.21% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | PD173074 |
| Description | PD173074 is an effective FGFR1 inhibitor (IC50: 25 nM) and also inhibits VEGFR2 (IC50: 100-200 nM) in cell-free assays. The selectivity is higher ~1000-fold for FGFR1 than PDGFR and c-Src. |
| Cell Research | Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT.(Only for Reference) |
| Kinase Assay | In vitro kinase inhibition assays: Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl2, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-32P]ATP (5 μM ATP containing 0.4 μCi of [γ-32P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [32P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically. |
| In vitro | PD173074 dose-dependently inhibited the autophosphorylation of VEGFR2 (IC50: 100-200 nM) and FGFR1 (IC50: 1-5 nM). PD173074 dose-dependently inhibited FGF-2-promoted granule neuron survival (IC50: 12 nM), which was more than 1,000-fold higher than SU 5402 activity. PD173074 specifically inhibited FGF-2-mediated cell proliferation, differentiation and MAPK activation in oligodendrocyte lineage cells.PD173074 was an ATP-competitive inhibitor of FGFR1 (Ki: 40 nM).PD173074 also dose-dependently and potently inhibited the autophosphorylation of FGFR3 (IC50: 5 nM). In multiple myeloma cell lines, PD173074 was active against wild-type and FGFR3 mutant types.PD173074 caused a significant decrease in the viability of FGFR3-expressing KMS11 and KMS18 cells (IC50<20 nM). |
| In vivo | PD173074 dose-dependently inhibited the autophosphorylation of VEGFR2 (IC50: 100-200 nM) and FGFR1 (IC50: 1-5 nM). PD173074 dose-dependently inhibited FGF-2-promoted granule neuron survival (IC50: 12 nM), which was more than 1,000-fold higher than SU 5402 activity. PD173074 specifically inhibited FGF-2-mediated cell proliferation, differentiation and MAPK activation in oligodendrocyte lineage cells.PD173074 was an ATP-competitive inhibitor of FGFR1 (Ki: 40 nM).PD173074 also dose-dependently and potently inhibited the autophosphorylation of FGFR3 (IC50: 5 nM). In multiple myeloma cell lines, PD173074 was active against wild-type and FGFR3 mutant types.PD173074 caused a significant decrease in the viability of FGFR3-expressing KMS11 and KMS18 cells (IC50<20 nM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (19.1 mM), Suspension. 10% DMSO+90% Saline : < 10 mg/mL (19.1 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. Ethanol : 52.4 mg/mL (100.06 mM), Sonication is recommended. DMSO : 125 mg/mL (238.7 mM), Sonication is recommended. |
| Keywords | VEGFR2 | VEGFR | Vascular endothelial growth factor receptor | PD-173074 | PD173074 | PD 173074 | Insulin Receptor | Inhibitor | inhibit | IGF1R | Fibroblast growth factor receptor | FGFR1 | FGFR | EGFR | c-Src | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Ferulic Acid | Formamide | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Highly Selective Inhibitor Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY